Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Neuro-Ophthalmology Oculoplastics Optometry Retina Women's Health View All Courses
Course Type
Evaluation Supplement Multimedia Webinar Podcast In-Person Multi-part Collection
Search
Login

Treatment of Posterior Segment Disease: Exploring the Suprachoroidal Space

By: Sunil K. Srivastava, MD (Chair); Dilraj Grewal, MD; Steven Yeh, MD

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

Content Source 

This continuing medical education (CME) activity captures content from a live satellite symposium. 

Activity Description

This supplement highlights a panel discussion on the suprachoroidal space as a novel route of drug delivery for the treatment of retinal diseases such as uveitic macular edema, diabetic retinopathy/diabetic macular edema, and neovascular age-related macular degeneration. Through a series of case discussions, the faculty review data from key trials examining the suprachoroidal space injections and proper administration techniques, plus an engaging discussion on how these advanced therapies may alter the treatment landscape.

Target Audience

This certified CME activity is designed for retina specialists.

 

Expiration Date: Tuesday, February 28, 2023
Release Date: January 20, 2022

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Interpret results of key trials examining the suprachoroidal space injections for the treatment of retinal diseases and how new data may eventually influence practice.
  • Describe proper administration techniques of suprachoroidal injections, solutions to common challenges, and best practices in patient education and informed consent.
  • Differentiate future applications of suprachoroidal injections and how advanced therapies may alter the treatment landscape.

Accreditation and Designation Statement

This educational activity is provided by Evolve Medical Education LLC (Evolve).

Accreditation Statement
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

Sunil K. Srivastava, MD (Chair)

Surgical Retina Fellowship Director
Cleveland Clinic
Cole Eye Institute
Cleveland, OH

Dilraj Grewal, MD

Associate Professor of Ophthalmology
Duke Eye Center
Duke University School of Medicine
Durham, NC

Steven Yeh, MD

Truhlsen Eye Institute
University of Nebraska Medical Center 
Emory University School of Medicine
Adjunct Professor
Omaha, NE

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

The following faculty/staff members have the following financial relationships with ineligible companies.

Sunil K. Srivastava, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: AbbVie, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Clearside Biosciences, Eyevensys, Gilead, Jcyte,  Optos, Regeneron, Sanofi, Santen, and Novartis. Grant/Research Support: Allergan, Bausch + Lomb, Clearside Biosciences, Carl Zeiss, Meditec, EyePoint Pharmaceuticals, Eyevensys, Jcyte, Novartis, Sanofi, and Santen.

Dilraj Grewal, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, EyePoint Pharmaceuticals, Genentech, IvericBio, and Novartis.

Steven Yeh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Adverum, Bausch + Lomb, Clearside Biosciences, and Regenxbio.

The Evolve staff and planners have no financial relationships with commercial interests. Faith Hayden, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests. 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Retina Today, or Bausch + Lomb.

Begin Course